Proxy Results, Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) As reported in Item 5.07 below, at the 2025 Annual Meeting of Stockholders held on May 1, 2025 (the "Annual Meeting") of aTyr Pharma, Inc. (the "Company"), the Company's stockholders, upon the recommendation of the Company's Board of Directors (the "Board"), approved an amendment to the Company's 2015 Stock Option and Incentive Plan, as amended (the "2015 Stock Plan"), to increase the maximum number of shares of common stock reserved and available for issuance by 5,000,000 to 15,719,300. The amendment to the 2015 Stock Plan also, among other things, extends the term under which incentive stock options may be granted until February 26, 2035.

A summary of the 2015 Stock Plan, as amended, is set forth in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 19, 2025 (the "Proxy Statement"). The summary and the foregoing description of the 2015 Stock Plan, as amended, do not purport to be complete and are qualified in their entirety by reference to the full text of the 2015 Stock Plan, as amended, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The following proposals were submitted to the Company's stockholders at the Annual Meeting:

(1) The election of two Class I directors, as nominated by the Board, to hold office until the 2028 annual meeting of stockholders or until their successors are duly elected and qualified;

(2) The ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025;

(3) The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement; and

(4) The approval of an amendment to the 2015 Stock Plan.

The number of shares of common stock entitled to vote at the Annual Meeting was 88,858,612. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 69,286,552. All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.

The number of votes cast for and against and the number of votes withheld, abstentions and broker non-votes, as applicable, with respect to each matter voted upon at the Annual Meeting are set forth below. Voting results are, when applicable, reported by rounding fractional share voting down to the nearest round number.

Proposal 1 - Election of Class I Directors.

Proposal 2 - Ratification of the appointment of Ernst and Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025.

2

Proposal 3 - Approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement.

Proposal 4 - Approval of an amendment to the 2015 Stock Plan.